Table 1.
Clinical characteristics of the study population
| Characteristics | HF patients |
|---|---|
| Age (years) (median ± SE) | 65.0 ± 0.6 |
| Sex (male/female) | 17/1 |
| Diabetics (%) | 28 |
| BSA (m2) (median ± SE) | 1.8 ± 0.02 |
| GFR (ml/min) (median ± SE) | 64.2 ± 1.6 |
| Glucose (mg/dl) (median ± SE) | 105 ± 1.5 |
| Time from MI (months) (median ± SE) | 5.5 ± 10.6 |
| NYHA class (%) | 1 = 5; 2 = 55; 3 = 39; 4 = 1 |
| DD (mm) (median ± SE) | 62.5 ± 0.5 |
| SD (mm) (median ± SE) | 52.0 ± 0.5 |
| LVEF (%) (median ± SE) | 26.5 ± 0.4 |
| EDV (ml) (median ± SE) | 216.5 ± 2.7 |
| ESV (ml) (median ± SE) | 151.0 ± 2.2 |
| E/A (median ± SE) | 1.25 ± 0.1 |
| Medications (%) | |
| Oral antidiabetic agents | 15 |
| Insulin | 20 |
| Statins | 75 |
| ACEIs | 70 |
| β-Blockers | 80 |
| Aspirin | 95 |
| Loop diuretics | 85 |
| Nitrates | 35 |
ACEI angiotensin converting enzymes inhibitor, BSA body surface area, DD diastolic diameter, SD systolic diameter, E/A diastolic function ratio, EDV end-diastolic volume, ESV end-systolic volume, GFR glomerular filtration rate, LVEF left ventricular ejection fraction, MI myocardial infarction, NYHA New York Heart Association Functional Classification